Selenium Sleep Meta-analysis: What the Evidence Says
Selenium Sleep Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biom
Quick Answer
Selenium Sleep Meta analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public health sources, so conclusions should be framed as evidence aware guidance rather than medical advice.
Key Takeaways
- 01This page is generated only from sources stored in the Migaku evidence knowledge base.
- 02Current evidence mix: 1 preclinical study, 1 research article.
- 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
- 04This article is educational and does not replace care from a qualified clinician.
Selenium Sleep Meta-analysis: What the Evidence Says
Quick Answer
Selenium Sleep Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.
Key Takeaways
- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 preclinical study, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.
Evidence Map
| Source | Evidence type | Level | Date | Identifier |
|---|---|---|---|---|
| Marked Clinical Improvement in Parkinson’s Disease Following Double-Filtration Apheresis: A Case Report | preclinical study | 4 | 2026-06-12 | 10.2147/DNND.S594425 |
| Editorial: Prevention and treatment advancements in diabetic retinopathy | research article | 4 | 2026-02-18 | 10.3389/fendo.2026.1807742 |
What The Sources Report
- Previous treatments did not result in significant improvement of clinical symptoms. [Burgard Harald (2026); evidence level 4]
- Results showed increased values for LDL cholesterol (131 mg/dl), total cholesterol (219 mg/dl) while malondialdehyde-modified (MDA)-LDL a marker for fat oxidation was in the upper normal range (71 U/l), increased RANTES (Regulated And Normal T cell Expressed and Secreted) a marker for dental foci (58.4 ng/mL) and leaky gut with increased zonuline (48 ng/mL). [Burgard Harald (2026); evidence level 4]
- While there is a trend of decreasing the incidence of the most severe forms of DR in developed countries, the risk of vision-threatening forms of DR is still high, and the overall prevalence of DR is increasing due to the global diabetes epidemic. [Bulum Tomislav (2026); evidence level 4]
- In addition to selenium, vitamin D has been reported to be involved in DR pathogenesis, but results have been inconsistent.explore the relationship between vitamin D level and the risk of DR in 535 adult patients with type 2 diabetes mellitus (T2DM). [Bulum Tomislav (2026); evidence level 4]
How To Read This Evidence
Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.
Practical Interpretation
For selenium sleep meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.
Limits Of This First Pass
This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.
References
- Burgard Harald (2026). Marked Clinical Improvement in Parkinson’s Disease Following Double-Filtration Apheresis: A Case Report. DOI: 10.2147/DNND.S594425. PMCID: PMC13271051. PMID: 42312121. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13271051/
- Bulum Tomislav (2026). Editorial: Prevention and treatment advancements in diabetic retinopathy. DOI: 10.3389/fendo.2026.1807742. PMCID: PMC12956620. PMID: 41788770. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12956620/
Safety Note
Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.
FAQ
Frequently Asked Questions
Medically reviewed
Last reviewed August 9, 2026 by Migaku Evidence Review
Related content
